AAN 2022 Highlights
Discover developments surrounding treatment strategies and current issues regarding MS presented at AAN 2022:
- Watch “AAN 2022 – The most exciting developments from this year’s meeting”, a video presentation by Dr Le Hua
- View patient-focussed data on the impact in which SARS-CoV-2 has had on individuals with MS
- Compare the burden of nosocomial infections in hospitalised patients with MS versus non-MS
- GLIMPSE updates into the comparative effectiveness of cladribine and other disease modifying therapies (DMTs) in the treatment of MS with results from the MSBase registry
Introduction to updates in MS management
There is a rapid change in MS management as long-term data emerge on established therapies, with enhanced options for patient preferences to be balanced with the risks and benefits. In the following post-AAN 2022 interview with Dr Le Hua, she discusses:
- Balancing the efficacy and safety profiles of disease modifying therapies (DMTs) in MS
- An overview of long-term data released at AAN 2022
- Novel developments from this year’s AAN and other ways to help people with MS manage their symptoms
Updates on the impact of SARS-CoV-2 vaccinations and immune responses in MS
A meta-analysis conducted by Gombolay et al into the protective antibody responses (PARs) in pwMS (people with MS) on DMT regimens following SARS-CoV2 vaccination showed1:
- PARs were detected in 100% untreated pwMS , and up to 99% pwMS on DMT
- Varying rates of vaccine response are reported in pwMS
- Humoral responses are blunted in S1PM (Sphingosine 1 Phosphate Modulators) and anti-CD20 treatments; however, the majority develop cellular responses2
A comparison of nosocomial infections is hospitalised patients with and without MS
The rise in nosocomial infections is a growing threat to the general population, but more worryingly, for individuals with multiple sclerosis. The following study by Petrenchik and Briggs was tasked with the elucidation of the infection rate of hospitalised individuals with MS, in comparison to those without MS3:
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
AAN 2022 highlights: Interview with Dr Le Hua on the state of MS
Multiple sclerosis (MS) management is evolving rapidly, with long-term data on established therapies, new treatment options, the need to balance risk and benefit along with patient preferences, and more. In the following post-AAN 2022 interview, join Dr Le Hua as she discusses:
- Balancing the efficacy and safety profiles of disease modifying therapies (DMTs) in MS
- An overview of long-term data released at AAN 2022
- Novel developments from this year’s AAN and other ways to help people with MS manage their symptoms
Meet Dr Hua
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
References
- Gombolay G, Dutt M, Tyor W. Immune responses to SARS-CoV-2 vaccination in multiple sclerosis: a systematic review and meta-analysis (S5.007). Neurology. 2022;98(18 Supplement):181.
- Kelly H, Jakubecz C, Serra A, Abboud H. Post-vaccination Central Nervous System Inflammation at a Tertiary Neuroimmunology Clinic: Impact of Influenza, SARS-CoV-2, and Other Vaccines (P11-4.001). Neurology. 2022;98(18 Supplement):1968.
- Petrenchik L, Briggs F. The Burden of Opportunistic Infections in Hospitalized Multiple Sclerosis Patients: a United States population-based study of 25.8 million patients (S40.008). Neurology. 2022;98(18 Supplement):1780.
- Butzkueven H, Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, et al. Real-world Comparative Effectiveness and Persistence of Cladribine Tablets and Other Oral Disease-Modifying Treatments for Multiple Sclerosis from GLIMPSE: Results from the MSBase Registry (P12-4.003). Neurology. 2022;98(18 Supplement):1373.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.